CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. (CTMX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · CTMX · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
9
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
CytomX Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
CTMX insider buying and selling by quarter
CTMX insider selling · CTMX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · CTMX ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
CTMX executive sell shares · CTMX board member insider trading · CTMX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Mar 17, 2026 | Chu Yu-Waye Chief Medical Officer | Sale | 21,279 | $137K | Form 4 |
| Mar 17, 2026 | McCarthy Sean A. CEO · Director | Sale | 118,969 | $764K | Form 4 |
| Mar 17, 2026 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | 31,492 | $202K | Form 4 |
| Mar 17, 2026 | Ogden Christopher CFO | Sale | 19,323 | $124K | Form 4 |
| Feb 2, 2026 | Lester Rachael Chief Business Officer | Award | 20,000 | — | Form 4 |
| Feb 2, 2026 | Chu Yu-Waye Chief Medical Officer | Award | 75,000 | — | Form 4 |
| Feb 2, 2026 | BELVIN MARCIA SVP, Chief Scientific Officer | Award | 60,000 | — | Form 4 |
| Feb 2, 2026 | Ogden Christopher CFO | Award | 90,000 | — | Form 4 |
| Feb 2, 2026 | McCarthy Sean A. CEO · Director | Award | 210,000 | — | Form 4 |
| Jun 13, 2025 | Ogden Christopher CFO | Option | 37,500 | — | Form 4 |
| Jun 16, 2025 | Ogden Christopher CFO | Sale | 10,614 | $29K | Form 4 |
| Jun 13, 2025 | Ogden Christopher CFO | Sale | 1,641 | $5K | Form 4 |
| Jun 13, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Option | 37,500 | — | Form 4 |
| Jun 16, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | 13,884 | $37K | Form 4 |
| Jun 13, 2025 | McCarthy Sean A. CEO · Director | Option | 150,000 | — | Form 4 |
| Jun 16, 2025 | McCarthy Sean A. CEO · Director | Sale | 55,511 | $149K | Form 4 |
| Mar 18, 2025 | McCarthy Sean A. CEO · Director | Sale | 37,656 | $23K | Form 4 |
| Mar 18, 2025 | Ogden Christopher CFO | Sale | 8,551 | $5K | Form 4 |
| Mar 18, 2025 | Chu Yu-Waye Chief Medical Officer | Sale | 4,025 | $2K | Form 4 |
| Mar 18, 2025 | ROWLAND LLOYD A General Counsel | Sale | 10,203 | $6K | Form 4 |
| Mar 18, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | 19,512 | $12K | Form 4 |
| Feb 4, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Award | 57,500 | — | Form 4 |
| Feb 4, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Award | 30,000 | — | Form 4 |
| Feb 4, 2025 | Chu Yu-Waye Chief Medical Officer | Award | 57,500 | — | Form 4 |
| Feb 4, 2025 | Chu Yu-Waye Chief Medical Officer | Award | 56,000 | — | Form 4 |
Chu Yu-Waye
Chief Medical Officer
Date
Mar 17
Shares
21,279
Price
$6.42
Value
$137K
BELVIN MARCIA
SVP, Chief Scientific Officer
Date
Mar 17
Shares
31,492
Price
$6.42
Value
$202K
BELVIN MARCIA
SVP, Chief Scientific Officer
Date
Feb 2
Shares
60,000
Price
—
Value
—
BELVIN MARCIA
SVP, Chief Scientific Officer
Date
Jun 13
Shares
37,500
Price
—
Value
—
BELVIN MARCIA
SVP, Chief Scientific Officer
Date
Jun 16
Shares
13,884
Price
$2.69
Value
$37K
BELVIN MARCIA
SVP, Chief Scientific Officer
Date
Mar 18
Shares
19,512
Price
$0.60
Value
$12K
BELVIN MARCIA
SVP, Chief Scientific Officer
Date
Feb 4
Shares
57,500
Price
—
Value
—
BELVIN MARCIA
SVP, Chief Scientific Officer
Date
Feb 4
Shares
30,000
Price
—
Value
—
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About CTMX insider trading
CTMX insider trades
CytomX Therapeutics, Inc. (CTMX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Ogden Christopher (CFO), McCarthy Sean A. (CEO · Director), BELVIN MARCIA (SVP, Chief Scientific Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. CTMX insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For CytomX Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
CTMX insider trading · 5 questionsThe insiders of CytomX Therapeutics, Inc. (CTMX) include executives and directors such as Ogden Christopher (CFO), McCarthy Sean A. (CEO · Director), BELVIN MARCIA (SVP, Chief Scientific Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026